Get all your news in one place.
100's of premium titles.
One app.
Start reading
Fortune
Fortune
Erika Fry

DARK SECRETS: How eli lilly went from pharmaceutical slowpoke to 791 billion juggernaut | Rare Historical Photos

(Credit: Illustration by Ben Wiseman)

The good news about donanemab, Eli Lilly’s Alzheimer’s drug, reached CEO Dave Ricks on July 2 as he was hiking in a remote part of Colorado. 

The pharmaceutical company had slogged for 35 years and spent $8 billion to develop an effective treatment for the terrible memory-robbing disease. So when much-longed-for news of the Food and Drug Administration’s approval of the medicine finally arrived—in the middle of the Indianapolis pharmaceutical company’s annual shutdown week, with the CEO and most of his 20,000 U.S. employees on holiday—Ricks dialed into FaceTime for a quick impromptu celebration. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.